{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:08:41Z","timestamp":1792782521985,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"ICPO","award":["ICPO"],"award-info":[{"award-number":["ICPO"]}]},{"name":"ETH MedLab Fellowship","award":["ETH MedLab Fellowship"],"award-info":[{"award-number":["ETH MedLab Fellowship"]}]},{"DOI":"10.13039\/501100001711","name":"SNSF","doi-asserted-by":"crossref","award":["320030_188978"],"award-info":[{"award-number":["320030_188978"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Horizon 2020 EU","award":["884104"],"award-info":[{"award-number":["884104"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00259-025-07102-8","type":"journal-article","created":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T21:44:36Z","timestamp":1738532676000},"page":"2431-2443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"52","author":[{"given":"Philipp","family":"Ritt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Soza-Ried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Nicolai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horacio","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korbinian","family":"Krieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Katrina","family":"Mapanao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Rotger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Zhernosekov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Schibli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasko","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"7102_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333. https:\/\/doi.org\/10.3322\/caac.21708.","journal-title":"CA Cancer J Clin"},{"key":"7102_CR2","first-page":"6357","volume":"9","author":"JS Ross","year":"2003","unstructured":"Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr., Kaur P, Gray K, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357\u201362.","journal-title":"Clin Cancer Res"},{"key":"7102_CR3","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/pros.23311","volume":"77","author":"Z Novakova","year":"2017","unstructured":"Novakova Z, Foss CA, Copeland BT, Morath V, Baranova P, Havlinova B, et al. Novel monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA) as research and theranostic tools. Prostate. 2017;77:749\u201364. https:\/\/doi.org\/10.1002\/pros.23311.","journal-title":"Prostate"},{"key":"7102_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41391-020-00299-9","volume":"24","author":"MK Labriola","year":"2021","unstructured":"Labriola MK, Atiq S, Hirshman N, Bitting RL. Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies. Prostate Cancer Prostatic Dis. 2021;24:301\u20139. https:\/\/doi.org\/10.1038\/s41391-020-00299-9.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"7102_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/1078-0432.CCR-15-0820","volume":"22","author":"U Haberkorn","year":"2016","unstructured":"Haberkorn U, Eder M, Kopka K, Babich JW, Eisenhut M. New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy. Clin Cancer Res. 2016;22:9\u201315. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0820.","journal-title":"Clin Cancer Res"},{"key":"7102_CR6","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.2967\/jnumed.116.186767","volume":"58","author":"M Eiber","year":"2017","unstructured":"Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, et al. Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med. 2017;58:S67\u201376. https:\/\/doi.org\/10.2967\/jnumed.116.186767.","journal-title":"J Nucl Med"},{"key":"7102_CR7","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.2967\/jnumed.115.170167","volume":"57","author":"HR Kulkarni","year":"2016","unstructured":"Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Sayeg M, Leshch Y, et al. PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the Bad Berka experience since 2013. J Nucl Med. 2016;57:S97\u2013104. https:\/\/doi.org\/10.2967\/jnumed.115.170167.","journal-title":"J Nucl Med"},{"key":"7102_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85\u201390. https:\/\/doi.org\/10.2967\/jnumed.116.183194.","journal-title":"J Nucl Med"},{"key":"7102_CR9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s00259-017-3895-x","volume":"45","author":"FE von Eyben","year":"2018","unstructured":"von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, et al. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging. 2018;45:496\u2013508. https:\/\/doi.org\/10.1007\/s00259-017-3895-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7102_CR10","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","volume":"75","author":"MM Heck","year":"2019","unstructured":"Heck MM, Tauber R, Schwaiger S, Retz M, D\u2019Alessandria C, Maurer T, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol. 2019;75:920\u20136. https:\/\/doi.org\/10.1016\/j.eururo.2018.11.016.","journal-title":"Eur Urol"},{"key":"7102_CR11","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1007\/s00259-020-05082-5","volume":"48","author":"S Rasul","year":"2021","unstructured":"Rasul S, Hartenbach M, Wollenweber T, Kretschmer-Chott E, Grubmuller B, Kramer G, et al. Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:1650\u20137. https:\/\/doi.org\/10.1007\/s00259-020-05082-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7102_CR12","doi-asserted-by":"publisher","unstructured":"Hennrich U, Eder M. [177Lu]Lu-PSMA-617 (Pluvicto(TM)): The first FDA-approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals (Basel). 2022;15. https:\/\/doi.org\/10.3390\/ph15101292.","DOI":"10.3390\/ph15101292"},{"key":"7102_CR13","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1002\/anie.200704936","volume":"47","author":"CE Dumelin","year":"2008","unstructured":"Dumelin CE, Tr\u00fcssel S, Buller F, Trachsel E, Bootz F, Zhang Y, et al. A portable albumin binder from a DNA-encoded chemical library. Angew Chem Int Ed Engl. 2008;47:3196\u2013201. https:\/\/doi.org\/10.1002\/anie.200704936.","journal-title":"Angew Chem Int Ed Engl"},{"key":"7102_CR14","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1021\/acs.molpharmaceut.1c00932","volume":"19","author":"M Benesova","year":"2022","unstructured":"Benesova M, Guzik P, Deberle LM, Busslinger SD, Landolt T, Schibli R, et al. Design and evaluation of novel albumin-binding folate radioconjugates: systematic approach of varying the linker entities. Mol Pharm. 2022;19:963\u201373. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00932.","journal-title":"Mol Pharm"},{"key":"7102_CR15","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1021\/acs.molpharmaceut.8b00152","volume":"15","author":"CA Umbricht","year":"2018","unstructured":"Umbricht CA, Benesova M, Schibli R, M\u00fcller C. Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy. Mol Pharm. 2018;15:2297\u2013306. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00152.","journal-title":"Mol Pharm"},{"key":"7102_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4004-5","author":"J Kelly","year":"2018","unstructured":"Kelly J, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C Jr., Schlyer D, et al. Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors. Eur J Nucl Med Mol Imaging. 2018. https:\/\/doi.org\/10.1007\/s00259-018-4004-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7102_CR17","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00259-020-05022-3","volume":"48","author":"V Kramer","year":"2021","unstructured":"Kramer V, Fernandez R, Lehnert W, Jimenez-Franco LD, Soza-Ried C, Eppard E, et al. Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC. Eur J Nucl Med Mol Imaging. 2021;48:893\u2013903. https:\/\/doi.org\/10.1007\/s00259-020-05022-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7102_CR18","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.7150\/thno.40482","volume":"10","author":"LM Deberle","year":"2020","unstructured":"Deberle LM, Benesova M, Umbricht CA, Borgna F, B\u00fcchler M, Zhernosekov K, et al. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity. Theranostics. 2020;10:1678\u201393. https:\/\/doi.org\/10.7150\/thno.40482.","journal-title":"Theranostics"},{"key":"7102_CR19","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1007\/s00259-022-05837-2","volume":"49","author":"VJ Tschan","year":"2022","unstructured":"Tschan VJ, Borgna F, Busslinger SD, Stirn M, Rodriguez JMM, Bernhardt P, et al. Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49:3639\u201350. https:\/\/doi.org\/10.1007\/s00259-022-05837-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7102_CR20","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1021\/acs.molpharmaceut.1c00994","volume":"19","author":"F Borgna","year":"2022","unstructured":"Borgna F, Deberle LM, Busslinger SD, Tschan VJ, Walde LM, Becker AE, et al. Preclinical investigations to explore the difference between the diastereomers [177Lu]Lu-SibuDAB and [177Lu]Lu-RibuDAB toward prostate cancer therapy. Mol Pharm. 2022;19:2105\u201314. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00994.","journal-title":"Mol Pharm"},{"key":"7102_CR21","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2967\/jnumed.123.265524","volume":"64","author":"VJ Tschan","year":"2023","unstructured":"Tschan VJ, Busslinger SD, Bernhardt P, Grundler PV, Zeevaart JR, K\u00f6ster U, et al. Albumin-binding and conventional PSMA ligands in combination with 161Tb: biodistribution, dosimetry, and preclinical therapy. J Nucl Med. 2023;64:1625\u201331. https:\/\/doi.org\/10.2967\/jnumed.123.265524.","journal-title":"J Nucl Med"},{"key":"7102_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649\u201355.","journal-title":"Am J Clin Oncol"},{"key":"7102_CR23","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402\u201318. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"key":"7102_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2967\/jnumed.118.212233","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, et al. Detection efficacy of 18F-PSMA-1007 PET\/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J Nucl Med. 2019;60:362\u20138. https:\/\/doi.org\/10.2967\/jnumed.118.212233.","journal-title":"J Nucl Med"},{"key":"7102_CR25","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","volume":"49","author":"K Sj\u00f6green Gleisner","year":"2022","unstructured":"Sj\u00f6green Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49:1778\u2013809. https:\/\/doi.org\/10.1007\/s00259-022-05727-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7102_CR26","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.2967\/jnumed.112.106138","volume":"53","author":"MG Stabin","year":"2012","unstructured":"Stabin MG, Xu XG, Emmons MA, Segars WP, Shi C, Fernald MJ. RADAR reference adult, pediatric, and pregnant female phantom series for internal and external dosimetry. J Nucl Med. 2012;53:1807\u201313. https:\/\/doi.org\/10.2967\/jnumed.112.106138.","journal-title":"J Nucl Med"},{"key":"7102_CR27","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s00259-010-1422-4","volume":"37","author":"C Hindorf","year":"2010","unstructured":"Hindorf C, Glatting G, Chiesa C, Linden O, Flux G, Committee ED. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37:1238\u201350. https:\/\/doi.org\/10.1007\/s00259-010-1422-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7102_CR28","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2967\/jnumed.121.263072","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, et al. Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022;63:1651\u20138. https:\/\/doi.org\/10.2967\/jnumed.121.263072.","journal-title":"J Nucl Med"},{"key":"7102_CR29","doi-asserted-by":"publisher","unstructured":"Unterrainer LM, Beyer L, Zacherl MJ, Gildehaus FJ, Todica A, Kunte SC, et al. Total tumor volume on 18F-PSMA-1007 PET as additional imaging biomarker in mCRPC patients undergoing PSMA-targeted alpha therapy with 225Ac-PSMA-I&T. Biomedicines. 2022;10. https:\/\/doi.org\/10.3390\/biomedicines10050946.","DOI":"10.3390\/biomedicines10050946"},{"key":"7102_CR30","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1088\/0031-9155\/47\/17\/311","volume":"47","author":"GD Flux","year":"2002","unstructured":"Flux GD, Guy MJ, Beddows R, Pryor M, Flower MA. Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapy. Phys Med Biol. 2002;47:3211\u201323. https:\/\/doi.org\/10.1088\/0031-9155\/47\/17\/311.","journal-title":"Phys Med Biol"},{"key":"7102_CR31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267452","author":"Z Ells","year":"2024","unstructured":"Ells Z, Grogan TR, Czernin J, Dahlbom M, Calais J. Dosimetry of [177Lu]Lu-PSMA-targeted radiopharmaceutical therapies in patients with prostate cancer: A comparative systematic review and metaanalysis. J Nucl Med. 2024. https:\/\/doi.org\/10.2967\/jnumed.124.267452.","journal-title":"J Nucl Med"},{"key":"7102_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s00259-018-4096-y","volume":"46","author":"J Zang","year":"2019","unstructured":"Zang J, Fan X, Wang H, Liu Q, Wang J, Li H, et al. First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:148\u201358. https:\/\/doi.org\/10.1007\/s00259-018-4096-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7102_CR33","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00259-023-06470-3","volume":"51","author":"J Zang","year":"2024","unstructured":"Zang J, Wang G, Zhao T, Liu H, Lin X, Yang Y, et al. A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [177Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2024;51:871\u201382. https:\/\/doi.org\/10.1007\/s00259-023-06470-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7102_CR34","first-page":"634","volume":"46","author":"S Vallabhajosula","year":"2005","unstructured":"Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, et al. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med. 2005;46:634\u201341.","journal-title":"J Nucl Med"},{"key":"7102_CR35","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.eururo.2023.12.004","volume":"85","author":"KN Chi","year":"2024","unstructured":"Chi KN, Armstrong AJ, Krause BJ, Herrmann K, Rahbar K, de Bono JS, et al. Safety analyses of the phase 3 VISION trial of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur Urol. 2024;85:382\u201391. https:\/\/doi.org\/10.1016\/j.eururo.2023.12.004.","journal-title":"Eur Urol"},{"key":"7102_CR36","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41391-021-00349-w","volume":"24","author":"S Satapathy","year":"2021","unstructured":"Satapathy S, Sood A, Das CK, Mittal BR. Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer-a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2021;24:880\u201390. https:\/\/doi.org\/10.1038\/s41391-021-00349-w.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"7102_CR37","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Giesel FL, Stefanova M, Benesova M, Bronzel M, Afshar-Oromieh A, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57:1170\u20136. https:\/\/doi.org\/10.2967\/jnumed.115.171397.","journal-title":"J Nucl Med"},{"key":"7102_CR38","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00259-022-06092-1","volume":"50","author":"A Delker","year":"2023","unstructured":"Delker A, Schleske M, Liubchenko G, Berg I, Zacherl MJ, Brendel M, et al. Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T\/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging. Eur J Nucl Med Mol Imaging. 2023;50:1280\u201390. https:\/\/doi.org\/10.1007\/s00259-022-06092-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7102_CR39","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1007\/s00259-015-3125-3","volume":"42","author":"L Kabasakal","year":"2015","unstructured":"Kabasakal L, AbuQbeitah M, Aygun A, Yeyin N, Ocak M, Demirci E, et al. Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:1976\u201383. https:\/\/doi.org\/10.1007\/s00259-015-3125-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7102_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2967\/jnumed.123.265448","volume":"65","author":"K Herrmann","year":"2024","unstructured":"Herrmann K, Rahbar K, Eiber M, Sparks R, Baca N, Krause BJ, et al. Renal and Multiorgan safety of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer in the VISION dosimetry substudy. J Nucl Med. 2024;65:71\u20138. https:\/\/doi.org\/10.2967\/jnumed.123.265448.","journal-title":"J Nucl Med"},{"key":"7102_CR41","first-page":"3192","volume":"59","author":"SS Chang","year":"1999","unstructured":"Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192\u20138.","journal-title":"Cancer Res"},{"key":"7102_CR42","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.1200\/JCO.2005.05.160","volume":"23","author":"NH Bander","year":"2005","unstructured":"Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591\u2013601. https:\/\/doi.org\/10.1200\/JCO.2005.05.160.","journal-title":"J Clin Oncol"},{"key":"7102_CR43","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2967\/jnumed.122.264594","volume":"64","author":"J Brosch-Lenz","year":"2023","unstructured":"Brosch-Lenz J, Delker A, Volter F, Unterrainer LM, Kaiser L, Bartenstein P, et al. Toward single-time-point image-based dosimetry of 177Lu-PSMA-617 therapy. J Nucl Med. 2023;64:767\u201374. https:\/\/doi.org\/10.2967\/jnumed.122.264594.","journal-title":"J Nucl Med"},{"key":"7102_CR44","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s00259-021-05446-5","volume":"49","author":"VJ Tschan","year":"2022","unstructured":"Tschan VJ, Borgna F, Schibli R, M\u00fcller C. Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands. Eur J Nucl Med Mol Imaging. 2022;49:470\u201380. https:\/\/doi.org\/10.1007\/s00259-021-05446-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7102_CR45","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1007\/s00259-018-4042-z","volume":"45","author":"C Schmidkonz","year":"2018","unstructured":"Schmidkonz C, Cordes M, Schmidt D, Bauerle T, Goetz TI, Beck M, et al. 68Ga-PSMA-11 PET\/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:1862\u201372. https:\/\/doi.org\/10.1007\/s00259-018-4042-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7102_CR46","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2967\/jnumed.121.261906","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A, Wang H, Robertson A, Armstrong WR, Zaum R, Weber M, et al. Tumor sink effect in 68Ga-PSMA-11 PET: myth or reality? J Nucl Med. 2022;63:226\u201332. https:\/\/doi.org\/10.2967\/jnumed.121.261906.","journal-title":"J Nucl Med"},{"key":"7102_CR47","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60:517\u201323. https:\/\/doi.org\/10.2967\/jnumed.118.219352.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07102-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07102-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07102-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T06:17:41Z","timestamp":1748413061000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07102-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["7102"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07102-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involving human patients were in accordance with the ethical standards of the institutional and national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study was approved by the regional ethics committee board (CEC SSM Oriente, permit 20210521) and written informed consent has been obtained from all individual patients included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare the following competing financial interest(s): Patent applications on PSMA ligands with albumin-binding entities have been filed by ITM Medical Isotopes GmbH, Germany and the Paul Scherrer Institute, Switzerland. KZ, RS and CM are listed as co-inventors. The authors further declare non-financial interest(s): non-carrier-added lutetium-177 was provided by ITM Medical Isotopes GmbH, Germany.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}